Losartan
- Generic Name
- Losartan
- Brand Names
- Hyzaar, Cozaar
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23ClN6O
- CAS Number
- 114798-26-4
- Unique Ingredient Identifier
- JMS50MPO89
- Background
Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Los...
- Indication
Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hyper...
- Associated Conditions
- Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke
- Associated Therapies
- -
A Study To Evaluate The Efficacy Of Eplerenone Compared With Losartan For The Treatment Of Patients With Mild To Moderate Hypertension
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2009-12-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 248
- Registration Number
- NCT00649311
- Locations
- 🇨🇳
Pfizer Investigational Site, Taipei, Taiwan
The Effect of Losartan on Atrial Fibrillation (AF) Burden and Pacemaker Dependence in Patients With Sick Sinus Syndrome
- First Posted Date
- 2008-03-31
- Last Posted Date
- 2010-04-01
- Lead Sponsor
- Chung Shan Medical University
- Target Recruit Count
- 220
- Registration Number
- NCT00647257
- Locations
- 🇨🇳
Chung Shan Medical University Hospital, Taichung, Taiwan
Safety of Dual Blockage of Rennin-angiotensin System in Patients With Advanced Renal Insufficiency
- Conditions
- Interventions
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2016-04-05
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 309
- Registration Number
- NCT00630708
- Locations
- 🇨🇳
Renal Division, Nanfang Hospital,Southern Medical University, Guangzhou, Guangdong, China
Atacand (Candesartan) Real Life Study
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2010-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14000
- Registration Number
- NCT00620178
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Antihypertensive Response to Losartan and Genetic Polymorphisms
- First Posted Date
- 2008-02-18
- Last Posted Date
- 2009-07-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 800
- Registration Number
- NCT00617877
Attenuation of Cardiac Effects of Arteriovenous Fistula Creation With Losartan
- Conditions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Melbourne Health
- Target Recruit Count
- 52
- Registration Number
- NCT00602004
- Locations
- 🇦🇺
Royal Melbourne Hospital, Parkville, Australia
Losartan Versus Atenolol for the Treatment of Marfan Syndrome
- First Posted Date
- 2008-01-15
- Last Posted Date
- 2012-07-12
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 17
- Registration Number
- NCT00593710
- Locations
- 🇨🇦
Children's Heart Centre, British Columbia's Children's Hospital, Vancouver, British Columbia, Canada
An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))
- Conditions
- Interventions
- First Posted Date
- 2007-12-05
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 306
- Registration Number
- NCT00568178
Adiponectin in Obese Women With T2DN and Effects by RAS Blocker
- Conditions
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2007-11-21
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 80
- Registration Number
- NCT00561704
PPARgamma Activation by Losartan in Hypertensive Patients: The Importance of Losartan-Metabolites
- Conditions
- Interventions
- First Posted Date
- 2007-11-20
- Last Posted Date
- 2007-11-20
- Lead Sponsor
- German Heart Institute
- Registration Number
- NCT00561327
- Locations
- 🇩🇪
German Heart Institute, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.